• Presented at TOXINS 2019

  • Collaborator: Ipsen

  • Authors: Wein T, Patel A, Bahroo L, Wilczynski O, Rios C, Murie-Fernandez M

Botulinum toxin type A (BoNT-A) is a recommended pharmacological option for patients with spasticity, and its anti-spastic effects have been demonstrated in stroke and central nervous system lesions, multiple sclerosis and cerebral palsy. The aim of this study is to understand the impact of fewer BoNT-A injections from patient and caregiver perspectives.